In this week’s episode of the DeviceTalks Weekly Podcast, Jeff Mirviss, executive vice president of Boston Scientific’s peripheral business, explains why the specialty’s name doesn’t really reflect the importance of arteries, veins and other critical “highways” that his business group is addressing.
Mirviss explains where the peripheral business is headed, and why Boston Scientific is uniquely positioned to address the business.
He also shares lessons learned over his 20-plus years at Boston Scientific including the challenges presented by the Guidant acquisition and the necessary spirit infused by CEO Michael Mahoney.
Also on this week’s podcast, Eric Kolodziej, corporate vice president and global head quality and regulatory affairs at Hologic, about how clinical trial management is changing. What role will real world evidence play going forward, and how will Hologic and others follow up on the record number of EUA’s issued over the past yea…